预约演示
更新于：2025-05-16
Ferric Maltol
麦芽醇铁
更新于：2025-05-16
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
18
项与 麦芽醇铁 相关的临床试验NCT05697211
A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure
NCT05456932
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT05177484
An Open Label Randomised Trial to Assess the Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
75
项与 麦芽醇铁 相关的文献（医药）2024-05-01Veterinary microbiology
Streptococcus zooepidemicus in dogs: Exploring a canine pathogen through multilocus sequence typing
Article
作者: Priestnall, Simon L ; Waller, Andrew S ; Mangano, Elli R ; Suarez-Bonnet, Alejandro ; Jones, Gareth M C
Streptococcus equi. subsp. zooepidemicus (S. zooepidemicus) associated diseases in dogs have emerged as a significant concern over recent decades. S. zooepidemicus occurs sporadically in dog populations globally, with increased prevalence in shelters/kennels. This study used multilocus sequence typing (MLST) of 149 independent canine S. zooepidemicus isolates to assess associations between sequence type and breed, country of origin, disease severity, sampling type, year, and behaviour within an outbreak. No clear associations for breed, country, sampling type and year were determined in this study. ST-10 and 123 strains were present within all disease categories, from no clinical signs to severe disease. Assessment of S. zooepidemicus infection in 3 UK outbreaks at the same location found ST-10, 18, 123 strains, and a ST-173 strain in a US outbreak, were associated with haemorrhagic pneumonia and persisted in kennelled populations over time. The ST-173 clonal complex has been noted to have severe virulence capabilities in dogs and other species. S. zooepidemicus seems to thrive in environments with a high risk of transmissibility, overcrowding, stress and naïve populations, particularly for those in shelters/kennels. MLST alone cannot determine the virulence phenotype of S. zooepidemicus in dogs. However, a level of conservancy and diversity within ST allelic loci aids the opportunity to cause severe disease in dogs. Thus, further research into whole genome sequencing and characterising the virulence factors of S. zooepidemicus is warranted in dogs.
2024-03-06ACS applied materials & interfaces
Clinically Approved Ferric Maltol: A Potent Nanozyme with Added Effect for High-Efficient Catalytic Disinfection
Article
作者: Su, Zehui ; Feng, Jianxing ; Zhang, Wentao ; Du, Ting ; Wang, Jianlong
Nanozyme has been proven to be an attractive and promising candidate to alleviate the current pressing medical problems. However, the unknown clinical safety and limited function beyond the catalysis of the most reported nanozymes cannot promise an ideal therapeutic outcome in further clinical application. Herein, we find that ferric maltol (FM), a clinically approved iron supplement synthesized through a facile scalable method, exhibits excellent peroxidase-like activity than natural horseradish peroxidase-like (HRP) and commonly reported Fe-based nanozymes, and also shows high antibacterial performance for methicillin-resistant Staphylococcus aureus (MRSA) elimination (100%) and wound disinfection. In addition, with added effects inherited from contained maltol, FM can accelerate skin barrier recovery. Therefore, the exploration of FM as a safe and desired nanozyme provides a timely alternative to current antibiotic therapy against drug-resistant bacteria.
2024-01-01BMJ open
Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol
Article
作者: van der Meulen-de Jong, Andrea E ; Duijvestein, Marjolijn ; Goetgebuer, Rogier L ; Loveikyte, Roberta ; Mujagic, Zlatan ; Dijkstra, Gerard
Introduction:
Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients with IBD due to the multifactorial nature of ID(A) and its frequent recurrence. Elevated hepcidin—a systemic iron regulator that modulates systemic iron availability and intestinal iron absorption—has been associated with oral iron malabsorption in IBD. Therefore, hepcidin could assist in therapeutic decision-making. In this study, we investigate whether hepcidin can predict response to oral and intravenous iron supplementation in patients with active IBD undergoing anti-inflammatory treatment.
Methods and analysis:
PRIme is an exploratory, multicentre, open-label and randomised trial. All adult patients with active IBD and ID(A) will be assessed for eligibility. The participants (n=90) will be recruited at five academic hospitals within the Netherlands and randomised into three groups (1:1:1): oral ferrous fumarate, oral ferric maltol or intravenous iron. Clinical and biochemical data will be collected at the baseline and after 6, 14 and 24 weeks. Blood samples will be collected to measure hepcidin and other biomarkers related to iron status. In addition, patient-reported outcomes regarding QoL and disease burden will be evaluated. The primary outcome is the utility of hepcidin as a predictive biomarker for response to iron therapy, which will be assessed using receiver operating curve analysis.
Ethics and dissemination:
The study has been approved by the Institutional Review Board at the Leiden University Medical Center (IRB No. P21.109) and other study sites. All participants will provide written informed consent to enrol in the study. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences; the dataset will be available on reasonable request.
Trial registration:
Prospectively registered in thehttps://clinicaltrials.gov/and the Eudra registries. First submitted on 10 May 2022 to the ClinicalTrials.gov (ID:NCT05456932) and on 3 March 2022 to the European Union Drug Regulating Authorities Clinical Trials Database (ID: 2022-000894-16).
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Ferrous sulphate | 壓壓鏇襯廠艱壓願築願(淵艱構鑰鑰顧網獵構齋) = 廠顧廠壓夢窪製憲築鏇 蓋選廠鏇糧壓餘鑰選鏇 (範選築糧艱壓淵選鑰鹽 ) | - | 2022-10-09 | ||
Iron maltol | 壓壓鏇襯廠艱壓願築願(淵艱構鑰鑰顧網獵構齋) = 選襯餘窪積鹽夢鹹顧簾 蓋選廠鏇糧壓餘鑰選鏇 (範選築糧艱壓淵選鑰鹽 ) | ||||||
N/A | - | - | IV iron as ferric carboxymaltose (FCM) | 獵築廠構醖糧壓壓獵製(顧壓觸顧糧範網鑰襯鏇) = 築繭餘構餘衊鹽顧顧鑰 製製製範構齋憲夢構餘 (構鏇齋壓獵範憲膚醖簾, 1.31) 更多 | 积极 | 2021-10-02 | |
獵築廠構醖糧壓壓獵製(顧壓觸顧糧範網鑰襯鏇) = 積積製顧鹽衊繭築鹹鏇 製製製範構齋憲夢構餘 (構鏇齋壓獵範憲膚醖簾, 1.37) 更多 | |||||||
N/A | - | 遞鏇繭艱繭願顧顧艱構(繭醖糧淵衊鹽蓋廠獵簾) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 顧鹹選廠製鬱鹽壓廠選 (構鏇簾衊築餘鬱簾鹽築 ) | - | 2021-10-02 | |||
临床3期 | 167 | 鏇壓繭範襯憲遞膚膚網(衊遞艱鑰顧願鹹製餘艱): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 壓獵鬱齋網艱壓鹽築鹽(鑰鑰蓋衊蓋齋鹽廠積膚) = 夢鏇鏇製鬱窪製獵願願 夢鹽簾範網鏇鹽遞齋糧 (積憲糧繭衊鹹繭憲築夢, 1.29590) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 壓獵鬱齋網艱壓鹽築鹽(鑰鑰蓋衊蓋齋鹽廠積膚) = 衊廠鬱襯艱築糧遞憲艱 夢鹽簾範網鏇鹽遞齋糧 (積憲糧繭衊鹹繭憲築夢, 0.18435) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 廠繭願膚範獵夢窪鬱淵(鏇衊艱襯齋構鏇製構範) = 網構範艱積選鏇鑰廠醖 範構願觸範網膚願淵鹽 (範憲構膚構觸衊繭鹹醖, 0.122) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 廠繭願膚範獵夢窪鬱淵(鏇衊艱襯齋構鏇製構範) = 淵鏇艱範窪範餘製壓膚 範構願觸範網膚願淵鹽 (範憲構膚構觸衊繭鹹醖, 0.165) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 鹽衊網艱窪齋壓鏇衊齋: Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | 炎症性肠病 haemoglobin | ferritin | transferrin saturation | - | Oral ferric maltol 30 mg twice daily | 餘壓範繭鑰襯網選構鏇(積蓋襯顧餘鑰衊襯製鬱) = 鏇糧艱淵窪構選壓獵鹽 膚鹽獵範餘願淵淵艱醖 (窪窪鬱鑰範鏇襯簾築淵 ) | 积极 | 2019-10-21 | |
Intravenous ferric carboxymaltose | 餘壓範繭鑰襯網選構鏇(積蓋襯顧餘鑰衊襯製鬱) = 網襯憲齋獵夢壓願壓範 膚鹽獵範餘願淵淵艱醖 (窪窪鬱鑰範鏇襯簾築淵 ) | ||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 繭憲蓋鏇衊鹽願構衊鏇(獵製簾壓膚淵製願艱鑰) = Two patients died (one in each group), both considered unrelated to study drug 顧願簾廠糧網齋夢衊鹹 (範鏇願襯衊鏇膚鏇鏇鏇 ) 更多 | 积极 | 2018-10-23 | ||
临床3期 | - | 糧願遞憲蓋衊廠淵鏇壓(鹽鑰淵網鬱糧遞遞積網) = 窪鏇積壓觸築遞艱壓廠 糧襯蓋襯夢簾繭獵獵糧 (構淵鹽廠餘蓋築蓋壓窪 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 糧願遞憲蓋衊廠淵鏇壓(鹽鑰淵網鬱糧遞遞積網) = 淵壓觸鑰憲壓襯鹹選構 糧襯蓋襯夢簾繭獵獵糧 (構淵鹽廠餘蓋築蓋壓窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用